Revenue segments as reported by the company.

Service revenue

Product revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Charles River Laboratories

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Charles River Labs posts record revenue in Q4 2022

Charles River Laboratories delivered a robust performance in Q4 2022, achieving record revenue and exceeding earnings expectations.
While facing challenges such as NHP supply constraints and regulatory issues, the company showcased operational strength and strategic resilience.
Management's focus on addressing headwinds and exploring growth opportunities positions Charles River Laboratories for future success.
Navigating uncertainties in 2023, the company aims to maintain financial stability and drive growth through strategic initiatives.

Charles River Laboratories reports strong Q1 performance amidst NHP challenges

Charles River Laboratories (CRL) had a strong Q1 performance, exceeding expectations and narrowing 2023 guidance amidst NHP supply constraints impact.
Clients continue to choose Charles River for its expertise and solutions, with segments showing growth potential and disciplined capital deployment.
Challenges include NHP supply issues, margin impact concerns, and predicting demand trends, while opportunities lie in rebounding growth and market positioning.
Overall, Charles River remains focused on navigating challenges, leveraging strengths, and capitalizing on growth opportunities in the biopharmaceutical market.

Charles River Labs reports strong Q2 performance amidst market challenges

Charles River Laboratories (CRL) delivered a strong Q2 performance, facing challenges in the DSA segment but expecting improvements in various business segments. The company is capitalizing on its strengths in client mix and global footprint for NHP work, while addressing challenges such as inflationary pressures and aggressive pricing from competitors.

Charles River Labs surpasses Q3 expectations amidst client caution

Charles River Laboratories delivered a solid performance in Q3, exceeding earnings expectations despite challenges from cautious client spending and margin pressures. Strategic initiatives focusing on innovation, compliance, and cost-saving measures are key strengths. Opportunities in successful client support, advanced technology investments, and supply chain enhancements position the company for future growth.

Charles River Labs reports solid 2023 growth, eyes stable 2024

Charles River Laboratories reported solid revenue growth in 2023, with a focus on operational efficiency and revenue enhancement strategies.
While facing challenges like revenue decline in Q4 and fluctuating cancellation rates, the company is optimistic about stable client spending and growth opportunities in 2024.
With a strong performance in the pharma business and strategic acquisitions, Charles River Laboratories is poised for margin improvement and revenue expansion in the coming year.
The company's confidence in pricing strategy, supply stability, and potential for share gains highlight its competitive position and growth prospects.

Charles River Labs reports mixed Q1 results, eyes sequential improvements

Charles River Laboratories navigated mixed Q1 results with strong performances in Manufacturing and RMS segments.
Challenges include slow recovery in Discovery business and potential staff availability constraints in Safety Assessment.
Opportunities lie in sequential improvements in DSA, increased bookings, and careful management of demand environment.

Charles River Labs Q2 revenue declines, focuses on cost efficiency

Charles River Laboratories faces challenges from softening demand trends impacting revenue but is taking actions to streamline costs and optimize operations. Despite revenue decline, the company's manufacturing segment shows growth potential. Opportunities exist in cost savings initiatives and focusing on CDMO business growth.

Charles River Labs beats Q3 expectations, eyes biopharma opportunities

Charles River Laboratories (CRL) delivered strong financial performance in Q3, focusing on cost management and strategic growth initiatives. Despite challenges in the biopharmaceutical sector, opportunities exist in CDMO and Biologics Testing businesses.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.

Charles River (CRL) Inks CDMO Deal With Gates Institutes

ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisor.

Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Charles River (CRL) Partners to Reduce Animal Research Usage

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces an integrated program, funded by a $1.3 million grant, to develop an in vitro alternative to inhalation toxicology studies.

Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of a new CRADL® facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.

Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be avai.

Charles River Laboratories to Present at William Blair and Jefferies Conferences

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

Charles River (CRL) Launches Viral Vector Tech Transfer Program

The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with consistent earnings growth and strong free cash flow margins. CRL's steady Q1 performance and positive outlook for 2024 indicate potential for growth, particularly in its manufacturing solutions division.

Charles River Laboratories: Fair Valuation Against Fundamentals

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of viral vector contract development and manufacturing organization (CDMO) experience, the Company has designed a methodical program to drive successful, accelerated process transfer to its Maryland-based viral vector center of excellence (CoE) in as little as nine months.

Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development

LONDON--(BUSINESS WIRE)-- #lifesciences--Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River's sample management capabilities. Titian's Mosaic sample management software is already well-established within Charles River's Discovery division, where the company has used the platform for 12 years to support programs from hit-identification to candidate selection. This agreement aims to add significant new capabilities to Charles River's sampl.

Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Charles River (CRL) Banks on RMS Growth Amid Competition

Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%.

Charles River Laboratories Announces First-Quarter 2024 Results

Corporacion America Airports

Endava plc - ADR

Intel

Keysight

Texas Instruments

VeriSign

It's been a tremendous year for growth stocks. New technologies and increasing consumer adoption in fields such a semiconductors, electric vehicles, and generative AI have led to tremendous gains for growth stocks.

The 7 Best Growth Stocks to Buy in May 2024

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior e.

Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

ICON

Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

News for Charles River Laboratories Stock (CRL)